INTRODUCTION
Glioblastoma (GBM) is both the most common and lethal adult primary solid CNS malignancy (1) . The median overall survival ranges from 12-18 months when conventional therapy is utilized (2) . The poor outcome of this disease highlights the need for additional treatment modalities. Autologous tumor lysate-pulsed dendritic cell vaccine therapy may offer a high degree of tumor specificity for highly heterogenous tumors, such as GBM, and has demonstrated a tolerable safety and toxicity profile in Phase I and II trials (3) (4) (5) (6) .
While DC vaccine strategies have shown great promise, there are limitations with this treatment modality. Distinct subsets of patients in early clinical trials appear to derive dramatic benefit and long-term survival from the therapy, whereas in others, the course of the disease appears unaltered (7) . We theorize that the action of the autologous tumor lysate DC vaccine is to prime and/or boost an immune response against individualized, tumor-specific, mutated or overexpressed tumor-specific antigens. T lymphocyte clones specific for these antigens would then invade the tumor and mediate its destruction.
However, the precise identity of these targets are unknown and likely differ from tumor to tumor (and possibly spatially and temporally within the same patient), as evidenced by studies examining the antigen targets of expanded populations of tumor-infiltrating lymphocytes in other malignancies (8, 9) .
Reliable biomarkers, imaging modalities and/or peripheral blood immune monitoring 4 assays that can predict and characterize the immune and clinical responses generated by therapies, such as the DC vaccine, are currently still in development. Previously, our group demonstrated that intracellular cytokine signaling (specifically that of STAT1 and STAT5 T cells) correlated with survival and also that regulatory T-cell population shifts were associated with clinical outcome (10, 11) .
The presence, quantity and phenotype of tumor infiltrating lymphocytes (TILs) have been examined in various malignancies, including glioma, and found to correlate with prognosis and/or grade (12) (13) (14) . In the context of dendritic cell vaccination, we previously demonstrated that patients with a mesenchymal gene expression tumor subtype possessed an increased TIL infiltration measured by non-quantitative IHC, which correlated with longer survival after DC vaccination compared to patients with other gene expression signatures (7) .
In the present study, we used next generation deep sequencing of the TCRVβ CDR3 region to 1) quantitatively measure TIL content in tumors and 2) to compare the array of TCR sequences present (TCR repertoire) within a tumor to those in the peripheral blood of the same patient, and correlate these factors with survival after DC vaccination. This was performed in an attempt to generate a predictive model by which to assess which patients would potentially benefit, and are currently benefitting, from DC vaccination.
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Tracking TCR repertoire shifts in the systemic circulation and tumor after treatment is a means of detecting treatment associated immune responsiveness without the need to know the specificity of the receptors (15) . Examination of the TCR repertoire has previously been used to characterize the immune response to systemic, nonspecific immunotherapies, such as CTLA-4 and PD-1 blockade (16) (17) (18) . Based on this work, we hypothesized that a quantitative method to evaluate TIL content in glioblastomas could be utilized to predict survival independently of tumor subtypes assessed by gene expression analysis. We also utilized this NGS data to identify and track T cell populations found in the tumor with those in the systemic circulation (19) , and applied this technique to glioblastoma patients treated with autologous tumor lysate-pulsed DC vaccination.
METHODS

Patient characteristics from DC vaccination Trials
This study focused on 15 glioblastoma multiforme (GBM) patients from Phase I and Phase II DC vaccination trials at UCLA (9 newly diagnosed, 6 recurrent GBM) from whom adequate residual fresh-frozen tumor tissue for TIL analysis was available and for whom >2-year survival data was available. Patients were treated with autologous tumor lysate- 
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Preparation of Autologous Dendritic Cells (DC)
Monocyte-derived DCs were established from adherent peripheral blood mononuclear cells (PBMC) obtained through leukapheresis, as we have recently described (5) . All ex vivo DC preparations were performed in the UCLA-Jonsson Comprehensive Cancer Center GMP facility under sterile and monitored conditions. Briefly, adherent peripheral blood mononuclear cells PBMCs were obtained from patients via leukapheresis and transformed into monocyte-derived dendritic cells by culture in RPMI media supplemented with 10% autologous serum, 500 U/mL of IL-4 and 500 U/mL GM-CSF for 7 days. DCs were collected by vigorous rinsing and washing with a 0.9% NaCl solution. Flow cytometry was utilized in order to analyze the purity and activation status of the DC population using CD83, CD86, and HLA-DR (release criteria required >30% large cell gate being CD86+ and HLA-DR+).
DCs were pulsed (co-cultured) with autologous tumor lysate overnight prior to injection.
Treatment Schema
Baseline brain MRI scans were performed one month prior to initiation of immunotherapy and then bimonthly after the completion of the experimental treatment. Each vaccine dose was administered as an intradermal (i.d.) injection in the arm region below patient's axilla.
Patients were monitored for two hours after immunization at UCLA's Clinical and Translational Research Center (CTRC). Patients received three i.d. injections at biweekly intervals. TTP was calculated from the date of the first DC vaccination to the date at which MR imaging confirmed tumor progression. OS was calculated from the date of the first DC vaccination to the date of death from any cause.
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IHC Staining
Multiplex immunohistochemistry was preformed on patient FFPE tumor samples. Briefly, tissue was deparaffinized in xylene, followed by incubation in decreasing concentrations of ethanol. Heat-induced epitope retrieval was then conducted; tissue was submerged in a pH 9.0 Tris-EDTA solution while incubated in a pressure cooker. After cooling, tissue was blocked for one hour (with Dako antibody diluent) and stained at room temperature with an antibody to CD8 (Dako, clone C8/144B). Slides were then washed and stained with the TSA Plus Fluorescein System, respectively. Slides were mounted using a VectaShield HardSet Mounding Medium with DAPI. Three images per section were taken using a Perkin Elmer Vectra 2 Automated Quantitative Pathology imaging system, using the 20x objective.
An automated image analysis software program (Inform) was used to quantify the density of CD8 T cells/frame.
High-throughput TCRβ sequencing
After surgical resection, residual tumor not required for clinical diagnosis was collected from each patient for the experimental studies herein. Blood was washed and removed from the specimen; necrotic areas were subsequently removed. Prior to DNA isolation, quality control H&E staining was conducted to insure the presence of >20% tumor within the tissue. Genomic DNA was extracted from patient tumor samples, both pre-DC vaccination, and when available, post DC-vaccination. Genomic DNA was also isolated from patient PBMC samples collected prior to DC vaccination, 2 weeks following the 3 rd DC (20)), were carried out using the ImmunoSEQ platform at Adaptive Biotechnologies (Seattle, WA, USA). Briefly, a multiplexed PCR method was employed using a mixture of 60 forward primers specific to TCR Vβ gene segments and 13 reverse primers specific to TCR Jβ gene segments. Reads of 87 bp were obtained using the Illumina HiSeq System. Raw HiSeq sequence data were preprocessed to remove errors in the primary sequence of each read, and to compress the data. A nearest neighbor algorithm was used to collapse the data into unique sequences by merging closely related sequences, to remove both PCR and sequencing errors (21) (22) (23) . Samples in which >100 unique TCRs were identified within tumors were used in this study. The estimated TIL content was calculated as previously described (23) . Briefly, we quantified the amount of DNA input into the assay and converted this to the equivalent total number of nucleated cells, assuming The overlap of TCR sequences was calculated as previously published (19, 24) . Briefly, to assess the similarity of TCRB repertoires between tumor and PBMC samples from each patient, we used the metric of TCRB repertoire overlap. For two samples, a and b, we identified the n TCRB CDR3 sequences present in both samples, along with the sequencing read counts C of each sequence in each sample. TCRB repertoire overlap between samples was defined as the sum of the sequencing reads from shared TCRB sequences divided by the total number of sequencing reads observed in both samples, and ranges from 0 to 1. To transform this overlap metric into a distance metric, we calculated [(1/TCR Overlap)−1]. This distance metric is higher for less-related TCRB repertoires and ranges from 0 to infinity. This calculation roughly corresponds to the number of sequencing reads required (in excess of one) to expect one read from a TCRB rearrangement shared between the two samples. 
RESULTS
Baseline TIL density correlates with survival after vaccination
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Based on our earlier studies that correlated the clinical benefits of an autologous dendritic cell vaccine with the presence of TILs and the mesenchymal gene expression signature of glioblastoma (7), we hypothesized that the quantitative assessment of pretreatment TIL levels might be able to predict survival outcomes in our patient population without the need for gene expression profiling analysis.
To test this question, we performed next generation sequencing of the rearranged TCRVβ gene repertoire found in 15 patients for whom we had residual fresh-frozen tumor after harvesting for autologous tumor lysate as part of the vaccine preparation (specimen from resection prior to vaccination) and from the same patients if they recurred after DC vaccination and underwent another resection (5 such pairs were available).
Supplementary Table S1
outlines the clinical characteristics of these patients.
Next generation TCRVβ gene sequencing was also performed on each patient's PBMC obtained at the same time points (pre/post DC vaccination and at tumor progression) so that we had matched TCRVβ sequencing data from each patient's tumor(s) and PBMC.
Quantitative assessment of the tumor infiltrating T-cell content in the pre-vaccine specimens from all 15 patients was performed. Supplementary Table S2 lists the resulting values for TIL content, clonality, and TCR overlap derived from TCR sequencing analysis. As a control, multiplex immunofluorescent staining for T cells was performed (Supplementary Fig. S1 ). This staining confirmed that the vast majority of T cells were found within the tumor parenchyma itself, and not contaminants within the tumor blood vessels. We then correlated the estimated TIL content with TTP and OS in our patient population. The estimated TIL count of glioblastomas, prior to DC vaccination, was the In order to assess whether the prognostic role of TILs may be independent of DC vaccination, we performed TCR sequencing on an additional six GBM patients who did not receive immunotherapy (3 newly diagnosed and 3 recurrent GBM samples). To account for spatial TIL heterogeneity within the tumors, we also collected three different pieces of tumor for genomic DNA analysis. In these patients who did not receive immunotherapy, the estimated TIL content did not significantly correlate with TTP (HR=1.258; p=0.835) nor OS (HR=1.260; p=0.837; Supplementary Figure 2) , suggesting that the prognostic benefit of TIL is specifically relevant for patients who subsequently go on to receive immunotherapy.
We also dichotomized patients into high and low estimated TIL content groups, based on the top quartile versus the lower three quartiles. Patients in the top TIL quartile group had significantly longer TTP and OS compared to the lower three TIL quartiles (p = 0.0088 and p = 0.0038) (Fig. 1A and B 
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with the estimated TIL content derived from TCR sequencing (Fig. 1C) .
TCR overlap between tumor and blood are indicative of responses to vaccination
Although we showed that pretreatment TIL content could predict the clinical outcome for patients receiving DC vaccination, there remained a group of patient outliers who did not possess high pretreatment TIL content but may still have potentially benefitted from DC vaccination, given the survival differences with similar patients historically. In this subgroup of patients, we theorized that although the initial estimated TIL content might be low, the DC vaccination may have induced tumor-specific T-cell responses. By using the TCR sequences obtained from relapsed tumor (post-DC vaccination) we could potentially monitor the maintenance, gain, or loss of specific TCRs over the course of immunotherapy.
To test this hypothesis, we used NGS in order to sequence the CDR3 region of rearranged TCRβ genes from five patients for whom we had obtained both primary and relapsed tumor samples, and peripheral blood samples obtained before treatment, after treatment, and following tumor progression. The frequency of the top 25 clones in tumor biopsies at pretreatment and the frequency of these clones in pretreatment and post-treatment blood samples is outlined in Supplementary Fig. S3 . We found little overlap between the TCRVβ sequences identified in different patients.
We then evaluated whether the subset of unique TCR sequences found within each patient's tumor tissue could be detected in the peripheral blood. We defined this TCR 13 overlap as the percentage of unique TCRβ chain sequences identified within each tumor that was also present within the peripheral blood. By restricting our analysis just to the discrete TCR repertoire present within the tumor, we could then just compare the overlap of these unique TCR sequences with those in the systemic circulation (blood), and correlated this overlap index with survival. The two patients (1-708 and 17-232) who displayed the highest overlap between pretreatment tumor and pretreatment peripheral blood TCR sequences (Figures 2A and 2B) had the longest overall survival (28.7 months and 71.3 months, respectively). Furthermore, the high degree of TCR overlap persisted over time, including after DC vaccination, to when the tumor eventually relapsed and another surgical resection was warranted. Of note, patient 17-232 did have a tumor recurrence, but the actual cause of death was from a deep vein thrombosis and the associated pulmonary embolism, and not from tumor progression. Thus, these data suggest to us that this patient was continuing to mount an antitumor T-cell response, even at recurrence.
In contrast, patients 6-815 and 21-828 exhibited short survival (4.5 and 6.3 months, respectively), and demonstrated the smallest TCR overlap between pretreatment tumor and the pretreatment peripheral blood. This minimal degree of TCR overlap remained unchanged, even after DC vaccination and upon tumor relapse ( Fig. 2D and E) . we describe a new approach utilizing multiple analytes from a single TCR deep-sequencing assay to monitor and predict response to DC vaccination. We determined that the estimated TIL content of pretreatment tumor directly correlated with survival and was predictive of which patients would benefit from the therapy. The fraction of TCR sequences within tumors that can also be found systemically also correlated with clinical outcome and provided insight into the determinants of successful, antigen-specific, antitumor immune response.
We evaluated this novel technology on specimens from patients who had previously been 
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enrolled in clinical trials of autologous tumor lysate dendritic cell vaccines for the treatment of glioblastoma. As is often the case when working with such material, our study was limited in the number of patients with fully available sets of blood and tumor specimens. Part of our study required comparing initial tumors to recurrent tumors from the same patient and as such the number of initial-recurrent tumor pairs was even more limited. Our patient cohort was heterogeneous, and included patients who were both newly diagnosed and had recurrent GBM and somewhat varied by molecular status (although none bore an isocitrate dehydrogenase mutation). However, even with the small number and heterogeneous group of patients, we were able to successfully demonstrate that TCR sequencing data can help distinguish patients that will benefit and are benefitting from immunotherapy with the DC vaccine.
We showed that an increased estimated TIL content prior to therapy was associated with prolonged TTP and OS. All very long-term survivors in this trial had estimated TIL content in the top quartile. The correlations between estimated TIL content and TTP and OS argues that estimated TIL content in the initial tumor specimen may be used to select patients for DC vaccination and may be applicable to other immunotherapies as well. In contrast, TIL content was not associated with survival in patients who were not treated with immunotherapy. Thus, our data suggests that the use of TCR sequencing to predict such survival indices may be directly relevant only for patients undergoing immunotherapy treatments such as DC Vax. We also did not find a direct relationship between increased TCR clonality and survival in these patients, suggesting that a diverse, polyclonal T-cell response may be critical for effective antitumor immune responses. 
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Although TIL content was the strongest predictor of long-term survival after DC vaccination, a subset of patients did not possess high-pretreatment TIL content, but still appeared to benefit. As DC vaccination is administered systemically, we compared tumor to peripheral blood TCR overlap over the course of DC vaccination therapy to monitor the immune response and predict clinical outcome. Questions remain regarding whether the systemic immune response reflects that of the tumor environment, but we believe that overlap between the TCRs found within the peripheral blood compared to the tumor would indicate an immune environment supportive of an antitumor immune response and would be important for survival in our cohort of patients.
Analysis of the data suggested that DC vaccination patients could be categorized into 3 response groups (Fig. 4) 
